GoKawiilNovo Nordisk outlines growth strategy beyond weight-loss drugs amid Lilly rivalry
Novo Nordisk this week detailed plans to diversify its business beyond its blockbuster obesity and diabetes treatments, according to CNBC reporting. The move comes as the Danish drugmaker faces intensifying competition from Eli Lilly in the weight-loss drug market.